{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:39:59Z","timestamp":1783478399146,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91313303"],"award-info":[{"award-number":["91313303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31370900"],"award-info":[{"award-number":["31370900"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81330079"],"award-info":[{"award-number":["81330079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573446"],"award-info":[{"award-number":["81573446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20131282"],"award-info":[{"award-number":["BK20131282"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Clinical Science and Technology Project","award":["BL2012008"],"award-info":[{"award-number":["BL2012008"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.canlet.2015.12.014","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T18:23:20Z","timestamp":1450808600000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"372","author":[{"given":"Ahmed","family":"Elgehama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanwei","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.12.014_bib0010","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2015.12.014_bib0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.12.014_bib0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.12.014_bib0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.12.014_bib0035","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0040","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.12.014_bib0045","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood.V96.2.676","article-title":"Versatility of BCR\/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects","volume":"96","author":"Salomoni","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0055","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0060","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.12.014_bib0065","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.12.014_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib resistance in CML","volume":"274","author":"Volpe","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2015.12.014_bib0075","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0080","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.canlet.2015.12.014_bib0090","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrm2039","article-title":"Protein tyrosine phosphatases: from genes, to function, to disease","volume":"7","author":"Tonks","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"10.1016\/j.canlet.2015.12.014_bib0095","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/MCB.18.5.2965","article-title":"Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo","volume":"18","author":"LaMontagne","year":"1998","journal-title":"Mol. Cell. Biol"},{"key":"10.1016\/j.canlet.2015.12.014_bib0100","doi-asserted-by":"crossref","first-page":"32313","DOI":"10.1074\/jbc.M111.249060","article-title":"Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein","volume":"286","author":"Alvira","year":"2011","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.12.014_bib0105","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1002\/anie.200454237","article-title":"23-oxa-analogues of OSW-1: efficient synthesis and extremely potent antitumor activity","volume":"43","author":"Shi","year":"2004","journal-title":"Angew. Chem. Int. Ed Engl"},{"key":"10.1016\/j.canlet.2015.12.014_bib0110","doi-asserted-by":"crossref","first-page":"e1581","DOI":"10.1038\/cddis.2014.538","article-title":"SBF-1 exerts strong anticervical cancer effect through inducing endoplasmic reticulum stress-associated cell death via targeting sarco\/endoplasmic reticulum Ca(2+)-ATPase 2","volume":"5","author":"Li","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.canlet.2015.12.014_bib0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bcp.2012.04.006","article-title":"SBF-1, a synthetic steroidal glycoside, inhibits melanoma growth and metastasis through blocking interaction between PDK1 and AKT3","volume":"84","author":"Li","year":"2012","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2015.12.014_bib0120","first-page":"371","article-title":"Effect of ZD6474 on the proliferation of imatinib-resistant K562 cells","volume":"31","author":"Jia","year":"2010","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.canlet.2015.12.014_bib0125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/aps.2011.192","article-title":"Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro","volume":"33","author":"Tong","year":"2012","journal-title":"Acta Pharmacol. Sin"},{"key":"10.1016\/j.canlet.2015.12.014_bib0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bcp.2011.04.013","article-title":"Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis","volume":"82","author":"Shen","year":"2011","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2015.12.014_bib0135","doi-asserted-by":"crossref","first-page":"e79478","DOI":"10.1371\/journal.pone.0079478","article-title":"Inhibition of the PI3K\/Akt\/GSK3 pathway downstream of BCR\/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2\/M arrest and prominently enhances induction of apoptosis","volume":"8","author":"Kurosu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.12.014_bib0140","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/leu.2009.49","article-title":"Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway, in","author":"Naughton","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2015.12.014_bib0145","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2015.12.014_bib0150","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.17.6.865","article-title":"New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check","volume":"17","author":"O'Hare","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2015.12.014_bib0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol"},{"key":"10.1016\/j.canlet.2015.12.014_bib0160","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1038\/sj.onc.1205724","article-title":"Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571","volume":"21","author":"Klejman","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.12.014_bib0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4161\/auto.22259","article-title":"BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide","volume":"9","author":"Goussetis","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2015.12.014_bib0170","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood-2012-01-402578","article-title":"Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide","volume":"120","author":"Goussetis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.12.014_bib0175","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2337\/db06-1160","article-title":"Ubiquitinated-protein aggregates form in pancreatic beta-cells during diabetes-induced oxidative stress and are regulated by autophagy","volume":"56","author":"Kaniuk","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.canlet.2015.12.014_bib0180","doi-asserted-by":"crossref","first-page":"24131","DOI":"10.1074\/jbc.M702824200","article-title":"p62\/SQSTM1 binds directly to Atg8\/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy","volume":"282","author":"Pankiv","year":"2007","journal-title":"J. Biol. Chem"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351500765X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351500765X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T04:10:48Z","timestamp":1599970248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438351500765X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S030438351500765X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.12.014","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}